{"doi":"10.1016\/j.ejca.2009.12.005","coreId":"136864","oai":"oai:bradscholars.brad.ac.uk:10454\/4563","identifiers":["oai:bradscholars.brad.ac.uk:10454\/4563","10.1016\/j.ejca.2009.12.005"],"title":"Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours.","authors":["Isambert, N.","Campone, M.","Bourbouloux, E.","Drouin, M.","Major, A.","Yin, W.","Loadman, Paul M.","Capizzi, R.","Grieshaber, C.","Fumoleau, P."],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2010","abstract":"noPURPOSE: C-1311 is a member of the novel imidazoacridinone family of anticancer agents. This phase 1 trial was designed to investigate the safety, tolerability and preliminary anti-tumour activity of C-1311.\\ud\n\\ud\nPATIENTS AND METHODS: This was a phase 1, inter-subject dose escalating and pharmacokinetic study of intravenous (IV) C-1311, administered weekly during 3consecutive weeks followed by 1week rest (constituting 1 cycle) in subjects with advanced solid tumours.\\ud\n\\ud\nRESULTS: Twenty-two (22) patients were treated with C-1311, the highest dose given was 640mg\/m(2). All subjects experienced one or more treatment-related adverse events (AEs). The most frequently observed treatment-related AEs were neutropaenia and nausea (50% each), followed by vomiting (27%), anaemia (23%), asthenia (23%) and diarrhoea (18%). Most treatment-related AEs were of Common Terminology Criteria for Adverse Events (CTCAE) grades 1-2, except for the blood and lymphatic system disorders, which were primarily of grades 3-4. The recommended dose (RD) of C-1311 administered as once weekly IV infusions for 3weeks every 4weeks is 480mg\/m(2), with the dose limiting toxicity (DLT) being grade 4 neutropaenia lasting more than 7days. Treatment at this dose offers a predictable safety profile and excellent tolerability.\\ud\n\\ud\nCONCLUSION: The safety profile and preliminary anti-tumour efficacy of C-1311, observed in this broad-phase dose-finding study, warrants further evaluation of the compound","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Elsevier","rawRecordXml":"<record><header><identifier>\n        \n            \n                oai:bradscholars.brad.ac.uk:10454\/4563<\/identifier><datestamp>\n                2014-05-19T15:13:47Z<\/datestamp><setSpec>\n                com_10454_152<\/setSpec><setSpec>\n                col_10454_6342<\/setSpec>\n            <\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:doc=\"http:\/\/www.lyncode.com\/xoai\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:title>\n            \nEvaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours.<\/dc:title><dc:creator>\nIsambert, N.<\/dc:creator><dc:creator>\nCampone, M.<\/dc:creator><dc:creator>\nBourbouloux, E.<\/dc:creator><dc:creator>\nDrouin, M.<\/dc:creator><dc:creator>\nMajor, A.<\/dc:creator><dc:creator>\nYin, W.<\/dc:creator><dc:creator>\nLoadman, Paul M.<\/dc:creator><dc:creator>\nCapizzi, R.<\/dc:creator><dc:creator>\nGrieshaber, C.<\/dc:creator><dc:creator>\nFumoleau, P.<\/dc:creator><dc:subject>\nC1311<\/dc:subject><dc:subject>\nPhase 1 study<\/dc:subject><dc:subject>\nAnticancer agents<\/dc:subject><dc:subject>\nAnti-tumour activity<\/dc:subject><dc:subject>\nPharmacokinetics<\/dc:subject><dc:subject>\nImidazoacridinone<\/dc:subject><dc:subject>\nSafety and tolerability<\/dc:subject><dc:description>\nno<\/dc:description><dc:description>\nPURPOSE: C-1311 is a member of the novel imidazoacridinone family of anticancer agents. This phase 1 trial was designed to investigate the safety, tolerability and preliminary anti-tumour activity of C-1311.\\ud\n\\ud\nPATIENTS AND METHODS: This was a phase 1, inter-subject dose escalating and pharmacokinetic study of intravenous (IV) C-1311, administered weekly during 3consecutive weeks followed by 1week rest (constituting 1 cycle) in subjects with advanced solid tumours.\\ud\n\\ud\nRESULTS: Twenty-two (22) patients were treated with C-1311, the highest dose given was 640mg\/m(2). All subjects experienced one or more treatment-related adverse events (AEs). The most frequently observed treatment-related AEs were neutropaenia and nausea (50% each), followed by vomiting (27%), anaemia (23%), asthenia (23%) and diarrhoea (18%). Most treatment-related AEs were of Common Terminology Criteria for Adverse Events (CTCAE) grades 1-2, except for the blood and lymphatic system disorders, which were primarily of grades 3-4. The recommended dose (RD) of C-1311 administered as once weekly IV infusions for 3weeks every 4weeks is 480mg\/m(2), with the dose limiting toxicity (DLT) being grade 4 neutropaenia lasting more than 7days. Treatment at this dose offers a predictable safety profile and excellent tolerability.\\ud\n\\ud\nCONCLUSION: The safety profile and preliminary anti-tumour efficacy of C-1311, observed in this broad-phase dose-finding study, warrants further evaluation of the compound.<\/dc:description><dc:date>\n2010-12-13T13:50:46Z<\/dc:date><dc:date>\n2010-12-13T13:50:46Z<\/dc:date><dc:date>\n2010<\/dc:date><dc:type>\nArticle<\/dc:type><dc:identifier>\nIsambert, N., Campone, M., Bourbouloux, E., Drouin, M., Major, A., Yin W., Loadman, P., Capizzi, R., Grieshaber, C. and Fumoleau, P. (2010). Evaluation of the safety of C-1311 (SYMADEX) administered in a phase 1 dose escalation trial as a weekly infusion for 3 consecutive weeks in patients with advanced solid tumours. European Journal of Cancer, Vol. 46, No. 4, pp. 729-734.<\/dc:identifier><dc:identifier>\n90007276<\/dc:identifier><dc:identifier>\nhttp:\/\/hdl.handle.net\/10454\/4563<\/dc:identifier><dc:identifier>\nEuropean Journal of Cancer, (2010) Volume 46, Issue 4, Pages 729-734<\/dc:identifier><dc:language>\nen<\/dc:language><dc:relation>\nhttp:\/\/dx.doi.org\/10.1016\/j.ejca.2009.12.005<\/dc:relation><dc:publisher>\nElsevier<\/dc:publisher>\n<\/oai_dc:dc>\n<\/metadata>\n        <\/record>","journals":null,"language":null,"relations":["http:\/\/dx.doi.org\/10.1016\/j.ejca.2009.12.005"],"year":2010,"topics":["C1311","Phase 1 study","Anticancer agents","Anti-tumour activity","Pharmacokinetics","Imidazoacridinone","Safety and tolerability"],"subject":["Article"],"fullText":null}